Stock Financial Ratios


SNSS / Sunesis Pharmaceuticals, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price2.86
Volume73,500.00
Market Cap ($M)63.22
Enterprise Value ($M)18.76
Book Value ($M)21.02
Book Value / Share1.34
Price / Book21.76
NCAV ($M)32.30
NCAV / Share2.06
Price / NCAV8.88
Income Statement (mra) ($M)
Revenue2.54
EBITDA-36.46
Net Income-38.02
Balance Sheet (mrq) ($M)
Cash & Equivalents7.95
Cash / Share0.51
Assets15.07
Liabilities12.16
Quick Ratio3.95
Current Ratio3.95
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-1.81
Return on Assets (ROA)-0.88
Return on Equity (ROE)-1.81
Identifiers and Descriptors
CUSIP867328601
Central Index Key (CIK)1061027
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Other Related CUSIPS
867328901
867328950
867328700
867328900
867328951
Share Statistics
Common Shares Outstanding (M)34.25
Scoring Models
Piotroski F Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Liabilities Per Share0.78
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Retained Earnings Per Share-39.92
Intangibles Per Share0.00
Goodwill Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00
Assets Current Per Share0.87
Cash Per Share0.51
Minority Interest Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Property Plant And Equipment Per Share0.00
Inventory Raw Materials Per Share0.00
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Assets Other Non Current Per Share0.09
Assets Other Current Per Share0.00
Accounts Payable Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Inventory Per Share0.00
Additional Paid In Capital Per Share39.05
Liabilities And Stock Equity Per Share0.96
Equity Per Share0.19
Inventory Work In Progress Per Share0.00
Property Plant And Equipment Net Per Share0.00
Cash And Equivalents Per Share0.51
Liabilities Current Per Share0.47
Assets Per Share0.96
Debt Per Share0.00
Deferred Income Tax Liabilities Per Share0.00

Related News Stories

Edison Issues Outlook on Sunesis Pharmaceuticals (SNSS)

2017-11-16 accesswire
LONDON, UK / ACCESSWIRE / November 16, 2017 / Sunesis (NASDAQ: SNSS) remains on track to complete the dose-escalation portion of its Phase Ib/II clinical trial for lead compound SNS-062, an oral Bruton's tyrosine kinase (BTK) inhibitor, in patients with confirmed Imbruvica resistance in mid-2018, and present initial safety and efficacy interim data in Q218. In addition, Sunesis is moving forward with SNS-510, a PDK1 inhibitor with potential activity across multiple tumor types, and we expect a decision from Takeda on the advancement of pan-Raf inhibitor TAK-580 by mid- to late 2018. (15-1)

Loxo Oncology: Several Catalysts In The Near To Medium Term

2017-11-13 seekingalpha
I've revisited this targeted oncology play a couple of times as the story continues to play out and management executes. (37-0)

ROTY Edition 1 Volume 48: Cutting A Position Loose And Promising Updates On Current Holdings

2017-11-08 seekingalpha
I remind readers the importance of constantly reevaluating current holdings in your brokerage accounts and questions to ask ourselves. (128-2)

Your Daily Pharma Scoop: Anxious Time For Dynavax Longs, VBL Therapeutics Gets A Boost, Roche Gets 2 FDA Approvals

2017-11-07 seekingalpha
This abridged "Daily Scoop" is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (414-5)

ROTY Volume 1 Edition 46: Bouncing Back In November And Several New Trades

2017-11-06 seekingalpha
Data from the TiNivo study makes AVEO Pharmaceuticals more attractive to me on multiple time frames and I review the presentation with readers below. (310-7)

CUSIP: 867328601